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Abstract
Background—The best treatment options for binge-eating disorder are unclear.
Purpose—To summarize evidence about the benefits and harms of psychological and 
pharmacologic therapies for adults with binge-eating disorder.
Data Sources—English-language publications in EMBASE, the Cochrane Library, Academic 
OneFile, CINAHL, and ClinicalTrials.gov through 18 November 2015, and in MEDLINE through 
12 May 2016.
Study Selection—9 waitlist-controlled psychological trials and 25 placebo-controlled trials that 
evaluated pharmacologic (n = 19) or combination (n = 6) treatment. All were randomized trials 
with low or medium risk of bias.
Requests for Single Reprints: Kimberly A. Brownley, PhD, Department of Psychiatry, University of North Carolina, CB #7175, 
Chapel Hill, NC 27599; kbrownle@med.unc.edu.
Current Author Addresses:
Dr. Brownley: Department of Psychiatry, University of North Carolina, CB #7175, Chapel Hill, NC 27599.
Drs. Berkman, Lohr, and Bann and Ms. Cullen: RTI International, PO Box 12194, Research Triangle Park, NC 27709.
Drs. Peat and Bulik: Department of Psychiatry, University of North Carolina, CB #7160, Chapel Hill, NC 27599.
Reproducible Research Statement: Study protocol: Available at www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-
reports/?pageaction=displayproduct&productID=1942. Statistical code and data set: In Methods and Results sections, respectively; 
full report is available at www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?
pageaction=displayproduct&productID=2157.
Current author addresses and author contributions are available at www.annals.org.
Author Contributions: Conception and design: N.D. Berkman, C.M. Peat, K.E. Cullen, C.M. Bulik.
Analysis and interpretation of the data: K.A. Brownley, N.D. Berkman, C.M. Peat, K.N. Lohr, C.M. Bann, C.M. Bulik.
Drafting of the article: K.A. Brownley, N.D. Berkman, C.M. Peat, K.N. Lohr, K.E. Cullen, C.M. Bann.
Critical revision for important intellectual content: K.A. Brownley, N.D. Berkman, C.M. Peat, K.N. Lohr, C.M. Bulik.
Final approval of the article: K.A. Brownley, N.D. Berkman, C.M. Peat, K.N. Lohr, K.E. Cullen, C.M. Bann, C.M. Bulik.
Statistical expertise: C.M. Bann.
Obtaining of funding: K.A. Brownley, N.D. Berkman, C.M. Peat, K.N. Lohr, C.M. Bulik.
Administrative, technical, or logistic support: N.D. Berkman, K.N. Lohr, K.E. Cullen.
Collection and assembly of data: K.A. Brownley, N.D. Berkman, C.M. Peat, K.E. Cullen, C.M. Bulik.
Disclosures: Dr. Brownley reports grants from the Agency for Healthcare Research and Quality during the conduct of the study, and 
personal fees from Shire and Sunovion Pharmaceuticals outside the submitted work. Dr. Lohr was an employee of RTI International–
University of North Carolina Evidence-Based Practice Center during the conduct of the study; received consulting fees from ECRI 
Institute outside the submitted work; and is vice president (unpaid) for PROMIS (Patient Reported Outcomes Measurement 
Information System), a 501(c)(3) foundation to support development and dissemination of patient-reported outcomes measurement 
systems. Dr. Bulik reports grants from Shire, personal fees from Ironshore, and textbook royalties from Pearson, outside the submitted 
work. Dr. Peat reports grants from Shire and membership on the BED advisory board of Sunovion Pharmaceuticals. Authors not 
named here have disclosed no conflicts of interest. Disclosures can be viewed at www.acponline.org/authors/icmje/
ConflictOfInterestForms.do?msNum=M15-2455.
HHS Public Access
Author manuscript
Ann Intern Med. Author manuscript; available in PMC 2017 October 12.
Published in final edited form as:
Ann Intern Med. 2016 September 20; 165(6): 409–420. doi:10.7326/M15-2455.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Data Extraction—2 reviewers independently extracted trial data, assessed risk of bias, and 
graded strength of evidence.
Data Synthesis—Therapist-led cognitive behavioral therapy, lisdexamfetamine, and second-
generation antidepressants (SGAs) decreased binge-eating frequency and increased binge-eating 
abstinence (relative risk, 4.95 [95% CI, 3.06 to 8.00], 2.61 [CI, 2.04 to 3.33], and 1.67 [CI, 1.24 to 
2.26], respectively). Lisdexamfetamine (mean difference [MD], −6.50 [CI, −8.82 to −4.18]) and 
SGAs (MD, −3.84 [CI, −6.55 to −1.13]) reduced binge-eating–related obsessions and 
compulsions, and SGAs reduced symptoms of depression (MD, −1.97 [CI, −3.67 to −0.28]). 
Headache, gastrointestinal upset, sleep disturbance, and sympathetic nervous system arousal 
occurred more frequently with lisdexamfetamine than placebo (relative risk range, 1.63 to 4.28). 
Other forms of cognitive behavioral therapy and topiramate also increased abstinence and reduced 
binge-eating frequency and related psychopathology. Topiramate reduced weight and increased 
sympathetic nervous system arousal, and lisdexamfetamine reduced weight and appetite.
Limitations—Most study participants were overweight or obese white women aged 20 to 40 
years. Many treatments were examined only in single studies. Outcomes were measured 
inconsistently across trials and rarely assessed beyond end of treatment.
Conclusion—Cognitive behavioral therapy, lisdexamfetamine, SGAs, and topiramate reduced 
binge eating and related psychopathology, and lisdexamfetamine and topiramate reduced weight in 
adults with binge-eating disorder.
Primary Funding Source—Agency for Healthcare Research and Quality.
Binge-eating disorder (BED), the most common eating disorder, affects approximately 3% 
of U.S. adults in their lifetime (1–3). It is characterized by recurrent (≥1 per week for 3 
months), brief (≤2 hours), psychologically distressing binge-eating episodes during which 
patients sense a lack of control and consume larger amounts of food than most people would 
under similar circumstances. Full diagnostic criteria are available in Appendix Table 1 
(available at www.annals.org). Binge-eating disorder is more common in women (3.5%) 
than men (2.0%) and in obese individuals (5% to 30%) (4, 5), especially those who are 
severely obese and those seeking obesity treatment (3, 6). It typically emerges in early 
adulthood (1, 7) but may surface in adolescence (8) and persist well beyond midlife (9). In 
May 2013, the American Psychiatric Association (APA) officially recognized BED as a 
distinct eating disorder with a lower diagnostic threshold (in terms of frequency and duration 
of symptoms) than formerly accepted (10). The numbers of persons presenting for 
evaluation, receiving a BED diagnosis, and requiring treatment are expected to increase (11, 
12).
BED is associated with poorer psychological and physical well-being, including major 
depressive and other psychiatric disorders (13, 14), relationship distress and impaired social 
role functioning (14–16), chronic pain (13, 14), obesity (13, 14, 17), and diabetes (18–21). 
Binge eating and BED predispose individuals to metabolic syndrome independent of weight 
gain (17), type 2 diabetes (22), earlier-onset diabetes (20), and worse diabetes-related 
complications and outcomes owing to nonadherence to recommended dietary modifications 
(23–25). Similarly, binge eating is implicated as a treatment-limiting factor in patients 
undergoing bariatric surgery, approximately 25% of whom experience “loss-of-control” 
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eating (26) that interferes with adherence to postsurgical nutritional recommendations and 
may impede weight loss and reduce quality of life (27, 28).
Treatment aims to reduce binge-eating frequency and disordered eating–related cognitions, 
improve metabolic health and weight (in patients who are obese, diabetic, or both), and 
regulate mood (in patients with coexisting depression or anxiety). Treatment approaches 
include psychological and behavioral treatments (hereafter “psychological”), pharmacologic 
treatments, and combinations of the 2 approaches. Table 1 describes common treatments for 
BED.
Current guidelines from the APA (29, 30) and the National Institute for Health and Care 
Excellence (NICE) (31) support the use of cognitive behavioral therapy (CBT) and selective 
serotonin reuptake inhibitors, but they differ in content and timing. The APA recommends a 
team approach (including psychiatrists, psychologists, dietitians, and social workers) with 
CBT as the cornerstone and medication as adjunctive therapy. In contrast, NICE 
recommends a CBT-based self-help approach but also endorses medication monotherapy as 
sufficient treatment for some patients. Best practices for weight management are unclear, in 
part because of different perspectives on dieting-based approaches (32, 33) and bariatric 
surgery (34–37) in obese individuals with BED. Moreover, little is known about the effect of 
patient-, provider-, and setting-level factors on treatment outcomes.
Our group at the RTI International–University of North Carolina Evidence-Based Practice 
Center conducted a systematic review for the Agency for Health-care Research and Quality 
(AHRQ) (38) that updates and extends the scope of our 2006 AHRQ review on eating 
disorders (39, 40) by including studies of loss-of-control eating, examining nearly twice as 
many randomized, controlled trials (RCTs) of BED therapies, and applying meta-analytic 
techniques to measure BED treatment effectiveness.
Methods
Our methods, complete search strategies, and detailed evidence tables are available in the 
full systematic review (38). Our protocol (41) was guided by key questions reflecting 
previously identified evidence gaps, input from key informants and a technical expert panel, 
and analytic frameworks depicting treatment effectiveness and harms (Appendix Figure 1, 
available at www.annals.org). Key questions focused on the effectiveness of psychological 
treatments compared with waitlist, pharmacologic treatments compared with placebo, and 
combination treatments compared with placebo or waitlist. Primary outcomes were 
behavioral (reducing binge-eating frequency and increasing abstinence from binge eating), 
psychological (improving levels of eating-related and general psychological outcomes), and 
physical (reducing weight and improving other markers of health where relevant), and also 
included harms from treatment.
Data Sources and Searches
We searched EMBASE, the Cochrane Library, Academic OneFile, CINAHL, and 
ClinicalTrials.gov from inception to 18 November 2015, and MEDLINE from inception to 
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12 May 2016 (Supplement, available at www.annals.org). We hand-searched reference lists 
and relevant systematic reviews.
Study Selection
We used a PICOTS (populations, interventions, comparators, outcomes, timing, settings, and 
study designs) approach to identify studies that met our inclusion and exclusion criteria. The 
population of interest was adults with a diagnosis of BED based on the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth or Fifth Edition. Interventions included 
pharmacologic, psychological, and behavioral treatments, as well as complementary and 
alternative medicine. We limited inclusion to RCTs that measured outcomes at the end of 
treatment or later in 10 or more randomly assigned patients; included active intervention, 
placebo, or waitlist control groups as comparators; were conducted in outpatient, inpatient, 
or home-based settings (such as self-help); and were published in English. We included trials 
conducted in any country. We selected abstracts for full-text review of articles if they met 
predefined inclusion and exclusion criteria (Appendix Table 2, available at www.annals.org). 
Two reviewers independently evaluated the full texts of selected articles to determine 
whether they should be included; disagreements were resolved by consensus discussion or 
with help from a third senior reviewer.
Data Abstraction and Risk-of-Bias Assessment
One reviewer abstracted details regarding study design, patient population, interventions and 
comparators, outcomes, duration of treatment and follow-up, settings, and results. A second 
reviewer checked the abstracted data for accuracy. For each study, 2 independent reviewers 
rated the risks of selection, performance, attrition, detection, and outcome reporting bias; 
they summarized their assessment overall as low, medium, or high risk of bias.
Statistical Analysis
For our investigation of treatments, we omitted studies with high risk of bias, except for 
harms and sensitivity analyses of meta-analyses. We graded the strength of evidence (SOE) 
for each major outcome with guidance from the Evidence-Based Practice Center regarding 
study limitations, consistency, precision, directness of the evidence, and risk of reporting 
bias (42, 43). The SOE grades are high, moderate, low, or insufficient, reflecting levels of 
confidence that the evidence represents the true effect. A grade of insufficient means that 
evidence either was unavailable or did not permit estimation of the effect. In this review, we 
report results with SOE grades of low, moderate, or high; see the technical report for more 
detailed results, including those with insufficient SOE (38).
For available trials using comparable treatment methods, durations, and outcomes, we 
performed an unadjusted random-effects meta-analysis using restricted maximum likelihood 
models (OpenMeta[Analyst] [Brown University Center for Evidence-Based Medicine]). 
Across studies, the percentage of patients achieving abstinence for each trial uses the 
number of all randomly assigned patients as the denominator to reflect a true intention-to-
treat analysis (that is, to correct variations in results of modified intention-to-treat analyses 
from individual trials). We derived risk ratios (RRs) for abstinence (defined as 0 binge 
episodes recorded in the most recent assessment period, usually the past month) and mean 
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differences (MDs) for binge episodes per week, binge days per week, eating-related 
obsessions and compulsions, body mass index (BMI), weight, and depression scores. We 
assessed statistical heterogeneity using the I2 statistic. In considering psychological studies 
for pooled analyses, we did not combine data from studies using different modes of delivery 
(for example, individual and group therapy) for the same treatment. If relevant, we 
conducted sensitivity analyses to measure the effect on pooled results of including studies 
rated high risk of bias. We also conducted qualitative syntheses of trials with interventions or 
outcomes that we judged insufficiently similar for meta-analysis.
Role of the Funding Source
This research was funded by AHRQ. Agency staff participated in developing the scope of 
the work, refining the analytic framework and key questions, resolving issues regarding the 
project scope, reviewing the draft report, and distributing it for peer review. AHRQ did not 
engage in selecting studies, assessing risk of bias, or synthesizing or interpreting data. The 
authors are solely responsible for the content and the decision to submit this manuscript for 
publication.
Results
Overview of Trials
We identified 34 trials with low or medium risk of bias (Appendix Figure 2 and Appendix 
Table 3, available at www.annals.org). Of these, 9 were waitlist-controlled psychological 
trials and 25 were placebo-controlled trials in which the active comparator was medication 
only (n = 19) or a combination treatment (n = 6). The psychological trials examined various 
forms of BED-focused CBT including self-help, psychodynamic interpersonal 
psychotherapy, dialectical behavior therapy, and behavioral weight loss treatment. The 
medication-only trials included anticonvulsants (topiramate and lamotrigine), antiobesity 
agents (orlistat), central nervous system stimulants (lisdexamfetamine), a dietary supplement 
(chromium picolinate), various second-generation antidepressants (SGAs; for example, 
citalopram, fluoxetine, and sertraline), and other medications (including acamprosate and 
armodafinil). Each of the 6 combination trials used a different behavioral plus medication 
approach.
Most trials (26 of 34) were conducted in the United States; the mean age ranged from 36 to 
47 years, and most participants were female (≥77%), white, and overweight or obese (mean 
BMI, 28.8 to 41.1 kg/m2). Trial sizes ranged from 24 to 394 randomly assigned participants, 
and treatment lasted 6 weeks to 6 months. Post-treatment follow-up assessments of the 
randomly assigned sample occurred in only 5 trials. Most studies excluded individuals 
receiving psychotropic medications; participants generally reported low to moderate levels 
of depression symptoms at baseline.
Sixteen trials contributed to the meta-analyses of key outcomes: 5 evaluated therapist-led 
CBT (44–48), 3 studied lisdexamfetamine (49–52), and 8 examined SGAs (fluoxetine, 60 
mg/d [53] or 80 mg/d [54]; bupropion [55]; citalopram [56]; duloxetine [57]; escitalopram 
[58]; fluvoxamine [59]; and sertraline [60]). In these trials, 342 participants were randomly 
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assigned to therapistled CBT or a waitlist, 416 to an antidepressant or placebo, and 983 to 
lisdexamfetamine or placebo. Of 583 patients randomly assigned to the lisdexamfetamine 
groups, our analysis included 517 who received at least 50 mg/d, because this is the 
minimum dosage approved by the U.S. Food and Drug Administration for BED treatment. 
We qualitatively synthesized data for additional outcomes from these as well as the 
remaining 18 trials.
Outcomes
For each outcome, we first present the meta-analytic results in the text and supporting 
figures, then present the results of trials not included in the meta-analysis. Table 2 
summarizes the qualitative findings for each trial, including the SOE grade for differences 
(or no differences) between interventions and comparators, which was low or moderate for 
all findings except one: weight reduction with lisdexamfetamine. Outcomes with insufficient 
SOE are not mentioned but may be found in the main report (38).
Binge-Eating Outcomes—More participants achieved abstinence from binge eating with 
therapist-led CBT versus waitlist (58.8% vs. 11.2%; RR, 4.95 [95% CI, 3.06 to 8.00]; I2 = 
0%; moderate SOE) (Figure 1), with lisdexamfetamine versus placebo (40.2% vs. 14.9%; 
RR, 2.61 [CI, 2.04 to 3.33]; I2 = 0%; high SOE) (Figure 2, top), and with SGAs versus 
placebo (39.9% vs. 23.6%; RR, 1.67 [CI, 1.24 to 2.26]; I2 = 0%; moderate SOE) (Figure 2, 
bottom). In addition, binge-eating frequency decreased with lisdexamfetamine (3 trials; MD 
in days/week −1.35 [CI, −1.77 to −0.93]; I2 = 99.68; high SOE) and SGAs (7 trials; MD in 
episodes/week, −0.67 [CI, −1.26 to −0.09]; moderate SOE; I2 = 0%; 3 trials; MD in days/
week, −0.90 [CI, −1.48 to −0.32]; I2 = 0%; low SOE). On the basis of qualitative syntheses, 
partially therapist-led CBT, guided self-help CBT, and topiramate increased binge-eating 
abstinence and reduced binge-eating frequency, and therapist-led CBT and structured self-
help CBT reduced binge-eating frequency (Table 2).
Eating-Related Psychological Outcomes—Lisdexamfetamine (3 trials; MD, −6.50 
[CI, −8.82 to −4.18]; I2 = 99.86; moderate SOE) and SGAs (3 trials; MD, −3.84 [CI, −6.55 
to −1.13]; I2 = 44.11%; low SOE) reduced eating-related obsessions and compulsions. On 
the basis of qualitative analyses, topiramate decreased eating-related obsessions and 
compulsions and therapist-led CBT and guided self-help CBT consistently improved eating-
related psychopathology, as reflected in participants’ susceptibility to hunger; cognitive 
control over eating; and overall concerns about eating, shape, and weight (Table 2).
Symptoms of Depression and Other Psychological and Psychosocial 
Outcomes—SGAs significantly reduced scores on the Hamilton Rating Scale for 
Depression (HAM-D) (3 trials; MD, −1.97 [CI, −3.67 to −0.28]; I2 = 48.62%; low SOE). 
Although individual pretreatment HAM-D scores ranged from 0 to 52, mean levels ranged 
from 2.6 to 5.7, leaving little room for clinically meaningful improvement. CBT (whether 
delivered in therapist-led, partially therapist-led, or structured self-help format) did not 
statistically significantly reduce depression symptoms (Table 2).
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Weight-Related Outcomes—Trials varied in reporting weight and BMI as outcomes. 
SGAs did not significantly reduce either BMI (6 trials; MD, −1.02 [CI, −2.62 to 0.59]; I2 = 
0%) or weight (4 trials; MD in kilograms, −3.92 [CI, −10.16 to 2.33]; I2 = 0%) (low SOE for 
no difference for both outcomes). On the basis of qualitative syntheses, reductions in BMI 
did not differ significantly between patients on waitlist and those receiving therapist-led, 
partially therapist-led, or structured self-help CBT (Table 2). In contrast, compared with 
placebo, lisdexamfetamine and topiramate resulted in greater weight reductions (Table 2). 
Several trials reported on weight-related metabolic variables; however, evidence was 
sufficient only for lisdexamfetamine reducing triglyceride levels compared with placebo 
(Table 2).
Harms Associated With Treatment
No psychological treatment studies reported harms. Of the 25 placebo-controlled 
medication-only or medication-plus-psychological intervention trials reviewed here, 20 
reported on harms. Most involved medication side effects widely documented in non-BED 
populations. Four serious adverse events occurred in the 3 lisdexamfetamine trials.
In pooled analyses of 3 trials, lisdexamfetamine led to more insomnia (RR, 2.80 [CI, 1.74 to 
4.51]; I2 = 0%) and general sleep disturbances (RR, 2.19 [CI, 1.36 to 3.54]; I2 = 31.65%) 
(both high SOE), as well as more headaches (RR, 1.63 [CI, 1.13 to 2.36]; I2 = 0%), 
gastrointestinal upset (RR, 2.71 [CI, 1.14 to 6.44]; I2 = 69.37%), and sympathetic nervous 
system (SNS) arousal (RR, 4.28 [CI, 2.67 to 6.87]; I2 = 62.93%) (all moderate SOE). 
Qualitatively, the incidence of decreased appetite with lisdexamfetamine, SNS arousal with 
topiramate and flvoxamine, and gastrointestinal upset and sleep disturbance with 
fluvoxamine was greater than that observed with placebo (Appendix Table 4, available at 
www.annals.org).
Treatment was discontinued infrequently, but approximately twice as often among patients 
assigned to medication alone or to a combined intervention (n = 98; 13 of whom had a 
serious adverse event) than in the placebo group (n = 43; 7 of whom had a serious adverse 
event). Participants dropped out of psychological trials most often because of dissatisfaction.
Discussion
This review contributes new knowledge from an expanded treatment evidence base that 
permitted estimates of treatment effect sizes and harms from pooled analyses of therapist-led 
CBT, lisdexamfetamine, and SGAs not provided in our 2006 AHRQ report (39) or in other 
recent reviews published before May 2016 (74–82). Our review included 15 new RCTs (4 
with CBT, 11 with medication) but excluded trials of sibutramine (which no longer is 
available in the United States), as well as studies of zonisamide, atomoxetine, and 
fluvoxamine that we rated as high risk of bias. Our findings provide strong support for 
therapist-led CBT, lisdexamfetamine, and SGAs (as a group) in helping patients with BED 
reduce binge-eating frequency and achieve abstinence; with less confidence, they suggest 
similar benefits from topiramate and other forms of CBT. Effect estimates varied in 
magnitude and cannot be compared easily across treatments because we could not do pooled 
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analyses on any single SGA and because the comparators for CBT and lisdexamfetamine 
differed (waitlist and placebo, respectively).
Patients seeking treatment for BED have various degrees of distress associated with binge 
eating–related obsessive thoughts and compulsions, worries about their shape and weight, 
and negative mood symptoms. With varying levels of certainty, our findings indicate that 
CBT in several formats, lisdexamfetamine, SGAs, and topiramate reduce these problems. 
The evidence from nearly 1000 patients was especially strong for lisdexamfetamine in 
reducing obsessions, compulsions, and weight. In overweight and obese individuals without 
BED, topiramate tends to induce weight loss (83), whereas SGAs tend to be weight-neutral 
(84), although individual responses to different SGAs may vary considerably. What remains 
unknown is whether reduced binge eating mediates weight loss in patients with BED treated 
with topiramate.
Despite the high levels of co-occurrence of BED with depression and other psychiatric 
conditions (85), we found no clear benefit of various forms of CBT in reducing symptoms of 
depression; limited evidence indicated a slight benefit with SGAs. This result may reflect 2 
factors: Included trials generally comprised participants with low levels of negative mood 
symptoms at baseline (and not necessarily a clinical diagnosis of depression), and CBT was 
tailored to address problematic eating-related cognitions and behaviors unique to BED rather 
than global depressive cognitions and behaviors.
Although the number of serious treatment harms was extremely low, harms of any type, 
discontinuation of treatment attributed to harms, and the number of serious adverse events 
were approximately 2-fold greater among those receiving an active medication than among 
those receiving a placebo. Based on meta-analytic and qualitative results, harms occurred 
more frequently in patients treated with lisdexamfetamine, topiramate, or fluvoxamine than 
in those receiving a placebo. The most commonly reported harm in all trials, SNS arousal, 
occurred more than 4 times as frequently with lisdexamfetamine than placebo.
Clinicians should be aware of the potential for lisdexamfetamine to decrease appetite. 
Depending on a patient’s treatment goals and propensity toward food restriction, this side 
effect may be helpful or harmful and should be monitored closely. Cycling between dietary 
restraint and binge eating is common among individuals with BED (86–88); many restrict 
food intake during the day and binge eat in the evening. In addition, many individuals with 
BED experience deficits in appetite awareness (89, 90). Theoretically, the potential for harm 
may be greater among these groups.
In January 2015, lisdexamfetamine became the first (and only) drug approved by the U.S. 
Food and Drug Administration for treating patients with BED. A central nervous system 
stimulant and dextroamphetamine pro-drug, lisdexamfetamine is recognized widely as an 
effective treatment for reducing symptoms of impulsivity, inattention, and hyperactivity in 
children and adults with attention deficit–hyperactivity disorder, in whom it is well-tolerated 
with generally manageable side effects, such as dry mouth, restlessness, insomnia, and 
gastrointestinal upset (91). Our meta-analyses show tolerability and efficacy of 
lisdexamfetamine in BED, including clinically meaningful short-term reductions in binge-
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eating frequency and in obsessive thoughts and compulsions regarding binge eating. Because 
the U.S. Drug Enforcement Administration classifies lisdexamfetamine as a Schedule II 
drug, individuals with a history of stimulant or other substance use disorder, suicide attempt, 
mania, or cardiac disease or abnormality were excluded from the trials; therefore, the results 
may not generalize to these BED populations.
In the United States, clinical practice guidelines tend to favor therapist-led CBT augmented 
with psychotropic medication (typically an antidepressant) as needed (29, 30). Many 
patients, however, have only limited access to BED-focused CBT with a BED-trained 
psychotherapist within a multidisciplinary team including a psychiatrist. The self-help 
approach recommended by NICE may be advantageous for overcoming this barrier to 
treatment access and increasing treatment dissemination. However, given the low SOE 
derived from our qualitative findings, recommending self-help CBT as first-line treatment 
would be premature. Our report cannot resolve the apparent discrepancy between the APA 
and NICE recommendations regarding when and how to integrate psychological, behavioral, 
and pharmacologic treatments for BED. Adequately powered head-to-head comparative 
effectiveness trials are needed to determine equivalence or noninferiority of self-help 
compared with therapist-led CBT.
Several limitations of the evidence base and review exist. The efficacy evidence base 
comprised only small samples or methodologically disparate single studies for nearly all 
medications, many psychological treatments, and all combination treatments. As a result, the 
evidence was insufficient to generate pooled estimates for self-help CBT or to evaluate the 
efficacy of specific antidepressants, promising interventions (such as interpersonal 
psychotherapy) (92, 93), complementary and alternative medicine or nutraceutical 
approaches, combination treatments (74, 82), or stepped-care strategies. Some trials had 
methodological limitations, including unclear randomization and allocation concealment, 
unmasked outcome assessors, and differential attrition between treatment groups. The 
instruments used to assess psychological outcomes, as well as how investigators reported 
outcomes, varied considerably. Moderate to high heterogeneity characterized the pooled 
estimates of some outcomes for some treatments, in several cases leading us to downgrade 
the SOE to moderate (for example, the effect of lisdexamfetamine on psychopathology and 
SNS arousal) or low (for example, the effect of SGAs on psychopathology). Studies did not 
report adverse events and discontinuations uniformly. Other limitations included trial setting 
(mainly supervised outpatient settings in U.S. academic research and medical centers) and 
population (mostly overweight or obese, 20- to 40-year-old white women with low levels of 
depression and anxiety), preventing us from assessing the effect of important patient 
characteristics, such as race, body weight, or presence of psychological or medical 
comorbidity, on treatment efficacy. Although publication bias and selective reporting were 
possible, many statistically nonsignificant results were reported in the trials, and a review of 
a sample of non-English abstracts (n = 358) and articles (n = 9) did not suggest a language 
bias or that any important psychological and medication trials were missing. Lastly, as no 
pharmacologic studies had long-term follow-up, persistence of efficacy benefits beyond 
active treatment could not be evaluated.
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Among adults with BED, strong evidence indicates that therapist-led CBT, 
lisdexamfetamine, and SGAs as a general class (mainly selective serotonin reuptake 
inhibitors) reduce the frequency of binge eating, increase the likelihood of achieving 
abstinence from binge eating, and improve other eating-related psychological outcomes. 
Similar but less compelling evidence shows a benefit from other forms of CBT and 
topiramate. Harms associated with lisdexamfetamine, SGAs, and topiramate rarely limited 
treatment. It is unclear whether these findings generalize to patients with BED beyond those 
included in these trials (chiefly, overweight or obese 20- to 40-year-old white women 
without psychological or medical comorbidity). Adequately powered trials are needed to 
evaluate the comparative long-term benefits of psychological and pharmacologic treatments. 
Given the high levels of association among BED, obesity, and depression, future studies 
should determine whether certain treatments are better suited for particular subsets of 
patients.
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Figure 1. 
Effect of therapist-led cognitive behavioral therapy on abstinence from binge eating.
RR = risk ratio.
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Figure 2. 
Effect of lisdexamfetamine, 50 or 70 mg/d (top), and second-generation antidepressants 
(bottom) on abstinence from binge eating.
RR = risk ratio.
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Appendix Figure 1. 
Analytic framework for treatment effectiveness and harms.
BMI = body mass index; GERD = gastroesophageal reflux disease; KQ = key question.
* Effectiveness of treatment.
† Differences between subgroups.
Brownley et al. Page 19
Ann Intern Med. Author manuscript; available in PMC 2017 October 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Appendix Figure 2. 
Flow diagram.
AHRQ = Agency for Healthcare Research and Quality.
* The figure was adapted from a larger report. Not all studies assessed for risk of bias are 
accounted for at the bottom of the figure because some populations are not included in the 
analysis in this article.
† Three studies (3 articles) also are included for binge-eating disorder treatment (key 
questions 1, 2, and 3) synthesis.
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Table 1
Interventions Commonly Used in Treating Patients With Binge-Eating Disorder
Treatment Description
Psychological, behavioral, or both
 CBT Focuses on identifying relationships among thoughts, feelings, and behaviors; aims to reduce negative 
emotions and undesirable behavior patterns by changing negative thoughts about oneself and the world. 
CBT may be delivered in various forms according to the level of therapist involvement—e.g., from 
therapist engaged in all aspects of treatment (therapist-led CBT) to no therapist engagement (self-help 
CBT). In self-help CBT, the patient follows a treatment manual or book, either with the help of a 
facilitator (e.g., guided or structured self-help) or alone. CBT may be tailored to the patient by focusing 
on problematic eating-related cognitions and behaviors.
 Dialectical behavior therapy Focuses on increasing mindfulness and developing skills to improve emotion regulation, distress 
tolerance, and interpersonal relationships to help patients respond to stress and negative affect more 
effectively.
 Interpersonal psychotherapy Focuses on identifying and changing the role of interpersonal functioning in causing and maintaining 
negative mood, psychological distress, and unhealthy behaviors.
 Behavioral weight loss Incorporates various behavioral strategies to promote weight loss, such as restricting caloric intake and 
increasing physical activity.
Pharmacologic
 Antidepressants Selectively inhibit reuptake of neurotransmitters involved in regulating mood and appetite (i.e., 
dopamine, norepinephrine, and serotonin). Common examples include bupropion, citalopram, 
desipramine, duloxetine, fluoxetine, fluvoxamine, and sertraline, which are indicated for treating patients 
with depression.
 Anticonvulsants Indicated for treating patients with epilepsy, bipolar disorder, major depression, and migraines. 
Topiramate, a carbonic anhydrase inhibitor, is the most commonly used.
 Antiobesity agents Used to treat obesity. For example, orlistat inhibits pancreatic lipase and thus decreases fat absorption in 
the gut.
 Central nervous system 
stimulants
Generally used to enhance or accelerate mental and physical processes; specifically used to treat 
attention deficit–hyperactivity disorder and certain sleep problems. Lisdexamfetamine, the only U.S. 
Food and Drug Administration–approved medication for binge-eating disorder, belongs to this class.
CBT = cognitive behavioral therapy.
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Appendix Table 1
DSM-5 Diagnostic Criteria for Binge-Eating Disorder
Definition, by Criteria Set
Criterion 1
 Recurrent episodes of binge eating characterized by both of the following:
a. Eating, in a discrete period of time (e.g., within any 2-hour period), an amount of food that is definitely larger than most people 
would eat in a similar period under similar circumstances
b. Sense of a lack of control over eating during the episode (e.g., a feeling that one cannot stop eating or control what or how much 
one is eating)
Criterion 2
 Binge-eating episodes are associated with 3 (or more) of the following:
a. Eating much more rapidly than normal
b. Eating until feeling uncomfortably full
c. Eating large amounts of food when not feeling physically hungry
d. Eating alone because of being embarrassed by how much one is eating
e. Feeling disgusted with oneself, depressed, or very guilty after overeating
Criterion 3
 Marked distress regarding binge eating is present.
Criterion 4
 Binge eating occurs, on average, at least 1 d/wk for 3 mo
Criterion 5
 Binge eating is not associated with regular use of inappropriate compensatory behavior (e.g., purging, fasting, excessive exercise) and does 
not occur exclusively during the course of anorexia nervosa or bulimia nervosa.
Severity grading, episodes/wk
 Mild: 1–3
 Moderate: 4–7
 Severe: 8–13
 Extreme: ≥14
DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (10).
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Appendix Table 2
Inclusion and Exclusion Criteria*
Category Criteria
Inclusion Exclusion
Population Individuals of all races, ethnicities, and cultural groups who met 
DSM-IV or DSM-5 criteria for BED
Co-occurring anorexia nervosa or bulimia 
nervosa
RCTs with fewer than 10 participants and 
nonrandomized studies with fewer than 50 
participants
Interventions Psychological, behavioral, pharmacological, or CAM treatments or 
combinations of treatments
Pharmacologic interventions not approved for 
marketing in the United States
Comparators Any active intervention described in the PICOTS criteria, placebo, or 
usual care
Pharmacologic interventions not approved for 
marketing in the United States
Study duration No limit None
Settings No limit; studies include inpatient, outpatient, or home-based settings 
for treatments such as self-help
None
Outcomes Intermediate and final health outcomes, and treatment harms. 
Intermediate health outcomes including biomarkers that can be linked 
directly to final physical health outcomes, such that an accumulation 
or worsening over time in that biomarker would result in the final 
health outcome
Studies that did not include at least 1 of the 
outcomes
Timing of outcome 
measurement
End of treatment or later Outcome measurement before study 
completion only
BED = binge-eating disorder; CAM = complementary and alternative medicine; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (10); DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; PICOTS = populations, interventions, 
comparators, outcomes, timing, and setting; RCT = randomized, controlled trial.
*
These criteria are a subset of those used in the full report (38), which included populations of individuals with loss-of-control eating and outcomes 
reflecting the course of illness.
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